Epoetin Alfa (Epogen)

Subscribe to Selected New Research on Epoetin Alfa

503 relevant articles (106 outcomes, 169 trials/studies) found for this Drug

Description: This recombinant erythropoietin, a 165-amino acid glycoprotein (about 62% protein and 38% carbohydrate), regulates red blood cell production. Epoetin alfa is produced by Chinese hamster ovary cells into which the human erythropoietin gene has been inserted. (USP Dictionary of USAN and International Drug Names, 1996).

Also Known As:

Epogen; Eprex

Relationship Network

Drug Context: Research Results

Biological Factors: 931

Intercellular Signaling Peptides and Proteins: 9177

Cytokines: 34131

Hematopoietic Cell Growth Factors: 11

Colony-Stimulating Factors: 1016

Erythropoietin: 6903

Recombinant Erythropoietin: 509

Epoetin Alfa: 503

Experts

1.	Williams, Denise: 10 articles (12/2007 - 06/2005)
2.	Henry, David H: 7 articles (02/2007 - 01/2004)
3.	Lefebvre, Patrick: 5 articles (02/2007 - 11/2005)
4.	Rossi, Greg: 5 articles (05/2006 - 11/2003)
5.	Epoetin Alfa Study Group: 5 articles (09/2004 - 06/2001)
6.	Wolfson, Marsha: 4 articles (07/2008 - 11/2006)
7.	Wilhelm, Francois E: 4 articles (12/2007 - 07/2006)
8.	Woodman, Richard C: 4 articles (12/2007 - 07/2006)
9.	Charu, Veena: 4 articles (07/2006 - 01/2004)
10.	Vercammen, Els: 4 articles (06/2006 - 12/2003)

Related Diseases

1.	Anemia 04/01/1993 - "For most patients, therapy with Epoetin alfa reverses anemia and provides them with many benefits, including an improved quality of life. " 08/01/2003 - "Epoetin alfa has proven efficacy and safety in correcting anemia and improving QOL based on numerous clinical studies and over a decade of clinical practice. " 04/01/1992 - "Epoetin alfa therapy has been proven effective in treating anemia in dialysis patients; it increases the hematocrit (HCT) and improves the quality of life. " 02/01/2006 - "Early treatment with epoetin alfa to correct anemia improved QOL in a statistically significant and clinically meaningful way, and improvements were greater in patients with baseline Hb levels >10.5 g/dl." 06/01/2004 - "CONCLUSION: Once-weekly epoetin alfa therapy is safe and effective for treating anemia in patients with CKD not on dialysis, and is associated with significant improvements in functional status and quality of life." Order ALL the reference details at left...
2.	Neoplasms (Cancer) 01/01/2005 - "This confirmed that QoL is correlated with haemoglobin levels and that treatment with epoetin alfa is associated with a significant improvement in QoL as measured by validated cancer-specific instruments such as FACT and CLAS. " 01/01/2004 - "These findings support the use of epoetin alfa to achieve gains in QOL and cancer treatment outcomes in anemic cancer patients and suggest that additional studies be conducted to further investigate the potential benefits of this agent in regard to improved outcomes." 01/01/2005 - "Treatment with epoetin alfa has repeatedly been shown to improve the quality of life (QoL) of cancer patients with anaemia. " 09/01/2001 - "Improvement in quality of life for cancer patients treated with epoetin alfa." 04/01/2009 - "METHODS: Cancer patients who have received at least one dose of epoetin alfa at the NCCS between January 1, 2005 and October 15, 2007 were included in this study. " Order ALL the reference details at left...
3.	Chronic Kidney Failure (Chronic Renal Failure) 02/01/1996 - "Epoetin alfa therapy has dramatically improved therapeutic responses and outcomes for anemic patients with end-stage renal disease. " 04/01/1998 - "Since this program's inception, advances in technology (e.g., better dialysis equipment) and pharmacology (e.g., maintenance of an optimum hematocrit with Epoetin alfa) have greatly improved the care of patients with ESRD and increased the potential for successful rehabilitation. " 01/01/2004 - "BACKGROUND: Anaemia correction in patients with end-stage renal disease has been enhanced following the use of epoetin alfa or beta and there are a number of studies detailing its application. " 01/01/2004 - "A study of the response of elderly patients with end-stage renal disease to epoetin alfa or beta." 03/01/1990 - "In studies to date, both subjective and objective data show that epoetin alfa therapy significantly improves the quality of life of patients with ESRD." Order ALL the reference details at left...
4.	Kidney Diseases (Kidney Disease) 01/01/2005 - "Eprex was administered intravenously to chronic kidney disease patients and, with improved storage and handling, there was a subsequent dramatic reduction in the number of cases. " 07/01/2008 - "BACKGROUND AND OBJECTIVES: Emerging evidence suggests that epoetin alfa can be administered at extended intervals of up to 4 wk. This open-label, randomized study was performed to characterize the pharmacokinetic and pharmacodynamic profiles of four dosing regimens of epoetin alfa administered subcutaneously in anemic patients who had chronic kidney disease and were not on dialysis. " 05/01/2007 - "The study patients had chronic kidney disease but were not receiving dialysis, had stable Hb levels of >or= 11.0 g/dL, and had been receiving epoetin alfa for >or= 2 months. " 08/01/2004 - "To evaluate the utility of a large-scale anti-EPO antibody screening program in patients with chronic kidney disease (CKD) administered epoetin alfa, a study involving 5 large renal centers in southern Ontario, Canada, was conducted. " 07/01/2008 - "CONCLUSIONS: Extended dosing interval regimens of epoetin alfa yielded modest pharmacokinetic differences but a similar pharmacodynamic response, suggesting that less frequent, higher dosages of epoetin alfa may be as effective as the current three-times-weekly regimen in anemic patients who have chronic kidney disease and are not on dialysis." Order ALL the reference details at left...
5.	Breast Neoplasms (Breast Cancer) 07/01/2009 - "Leyland-Jones et al. conducted a study evaluating the effects of early intervention with epoetin alfa (40,000 units administered subcutaneously every week) on survival and QOL of mainly nonanemic patients with metastatic breast cancer. " 10/01/2004 - "The findings of the study demonstrate for the first time in patients with breast cancer that epoetin alfa significantly enhances functional well-being, which translates into significantly better utility scores. " 09/01/2004 - "Although the study was not designed or powered for survival as an endpoint, Kaplan-Meier estimates for the full cohort showed a trend in overall survival favoring epoetin alfa treatment (P = 0.13, log rank test); a similar benefit was seen in the breast cancer subpopulation. " 10/01/2003 - "It appears that epoetin alfa is a useful addition to the treatment of breast cancer." 01/01/2003 - "OBJECTIVES: To determine the incremental cost utility of epoetin-alfa versus placebo in anaemic patients with stage IV breast cancer from a UK National Health Service perspective. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Hemoglobins (Hemoglobin)
2.	Erythropoietin
3.	darbepoetin alfa (Aranesp)
4.	Epoetin Alfa (Epogen)
5.	Platinum
6.	Ribavirin (Virazole)
7.	Recombinant Erythropoietin
8.	Iron
9.	Intercellular Signaling Peptides and Proteins (Growth Factors)
10.	Interferon-alpha (Interferon Alfa)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Blood Transfusion (Blood Transfusions)
3.	Erythrocyte Transfusion
4.	Renal Dialysis (Hemodialysis)
5.	Adjuvant Chemotherapy

Best Treatments:
Research Summary Report
on Anemia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1062 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>